Role of radiotherapy in refractory/relapsed classical Hodgkin lymphoma in the era of targeted therapies and immunotherapy
Sukeina Baouia, Rafik Nebbache, Côme Bommier, Florian Chevillon, Emmanuel Fardeau, Catherine Thieblemont, Laurent Quero · 2026
Read Role of radiotherapy in refractory/relapsed classical Hodgkin lymphoma in the era of targeted therapies and immunotherapy by Sukeina Baouia, Rafik Nebbache, Côme Bommier, Florian Chevillon, Emmanuel Fardeau, Catherine Thieblemont, Laurent Quero (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13320509.txt.
Description
Sukeina Baouia and co-authors review the place of radiotherapy in a 2026 article on Hodgkin lymphoma that has returned or resisted first treatment. Standard care for fit patients still pairs rescue drug therapy with a stem cell transplant using the patient's own cells. Newer drugs have changed what rescue care looks like before transplant.
Radiation now has a narrower, more tailored role, aimed at leftover disease, small areas of relapse, or spots that stay active on scans. It looks most helpful around transplant for patients with bulky disease or weak early response. Modern shaped and guided methods let teams adapt dose to response. Proof for pairing radiation with the newest drugs stays thin and mostly rests on small past studies.
Catalog record
| CREATOR | Sukeina Baouia, Rafik Nebbache, Côme Bommier, Florian Chevillon, Emmanuel Fardeau, Catherine Thieblemont, Laurent Quero |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37607 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |